FMR LLC discloses 8.5% Wave Life Sciences (WVE) stake in Schedule 13G

Rhea-AI Filing Summary

FMR LLC and Abigail P. Johnson report beneficial ownership of 15,020,982.62 shares of Wave Life Sciences Ltd. common stock, representing 8.5% of the class as of December 31, 2025. FMR LLC holds sole voting power over 15,016,629.00 shares and sole dispositive power over 15,020,982.62 shares.

Abigail P. Johnson is reported with sole dispositive power over 15,020,982.62 shares but no voting power. The securities are stated to be held in the ordinary course of business and not for the purpose of changing or influencing control of Wave Life Sciences.

Insights

Institutional Ownership Analyst

Large institutional holder reports an 8.5% passive stake in Wave Life Sciences.

FMR LLC, a major asset manager, reports beneficial ownership of 15,020,982.62 Wave Life Sciences common shares, equal to 8.5% of the class as of December 31, 2025. FMR has sole voting power over 15,016,629.00 shares and sole dispositive power over 15,020,982.62 shares.

Abigail P. Johnson is listed with sole dispositive power over the same 15,020,982.62 shares but no voting power, reflecting a control relationship rather than separate holdings. The certification states the position is held in the ordinary course of business and not to change or influence control of the company.

The filing characterizes this as a passive ownership position under Schedule 13G mechanics. Future changes in the reported percentage or a shift to a different filing type would typically appear in subsequent beneficial ownership reports if they occur.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

WAVE LIFE SCIENCES LTD

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

Y95308105

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. Y95308105

1

Names of Reporting Persons

FMR LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 15,016,629.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 15,020,982.62
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

15,020,982.62

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.5 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. Y95308105

1

Names of Reporting Persons

Abigail P. Johnson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 15,020,982.62
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

15,020,982.62

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.5 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: WAVE LIFE SCIENCES LTD
(b)	Address of issuer's principal executive offices: 7 STRAITS VIEW, #12-00,MARINA ONE EAST TOWER,SINGAPORE,U0,018936
Item 2.
(a)	Name of person filing: FMR LLC
(b)	Address or principal business office or, if none, residence: 245 Summer Street, Boston, Massachusetts 02210
(c)	Citizenship: Not applicable
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: Y95308105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 15020982.62
(b)	Percent of class: 8.5 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page.
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 15020982.62
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of WAVE LIFE SCIENCES LTD. No one other person's interest in the COMMON STOCK of WAVE LIFE SCIENCES LTD is more than five percent of the total outstanding COMMON STOCK.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See attached Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FMR LLC

Signature:	Stephanie J. Brown
Name/Title:	Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:	02/04/2026

Abigail P. Johnson

Signature:	Stephanie J. Brown
Name/Title:	Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
Date:	02/04/2026

Comments accompanying signature: * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.

FAQ

How much of Wave Life Sciences (WVE) does FMR LLC own?

FMR LLC reports beneficial ownership of 15,020,982.62 Wave Life Sciences common shares, representing 8.5% of the outstanding class as of December 31, 2025. FMR has sole voting power over 15,016,629.00 shares and sole dispositive power over 15,020,982.62 shares.

What stake in Wave Life Sciences (WVE) is attributed to Abigail P. Johnson?

Abigail P. Johnson is reported as beneficially owning 15,020,982.62 Wave Life Sciences common shares, or 8.5% of the class. She has sole dispositive power over these shares but no voting power, reflecting control through FMR LLC rather than separate, directly voted holdings.

Is FMR LLC’s ownership in Wave Life Sciences (WVE) considered passive or activist?

The filing certifies that the Wave Life Sciences shares were acquired and are held in the ordinary course of business, not for changing or influencing control. This language characterizes FMR LLC’s 8.5% position as a passive ownership stake under Schedule 13G rules.

What voting power does FMR LLC have over Wave Life Sciences (WVE) shares?

FMR LLC has sole voting power over 15,016,629.00 Wave Life Sciences common shares and no shared voting power. It also holds sole dispositive power over 15,020,982.62 shares, meaning it alone can decide how those shares are voted and disposed.

On what date is FMR LLC’s 8.5% Wave Life Sciences (WVE) ownership measured?

The 8.5% beneficial ownership of Wave Life Sciences common stock, totaling 15,020,982.62 shares, is measured as of December 31, 2025. That date is identified as the event date requiring the Schedule 13G beneficial ownership statement filing.

Does any other single investor hold over 5% of Wave Life Sciences (WVE) through FMR’s accounts?

The filing notes that one or more other persons may receive dividends or sale proceeds, but no single other person has an interest in Wave Life Sciences common stock representing more than 5% of the total outstanding shares through these holdings.